- Volume 14 Issue 3
DOI QR Code
Association Between MDM2 SNP309 T>G and Risk of Gastric Cancer: A Meta-analysis
- Tian, Xin ;
- Tian, Ye ;
- Ma, Ping ;
- Sui, Cheng-Guang ;
- Meng, Fan-Dong ;
- Li, Yan ;
- Fu, Li-Ye ;
- Jiang, Tao ;
- Wang, Yang ;
- Ji, Fu-Jian ;
- Fang, Xue-Dong ;
- Jiang, You-Hong
- Published : 2013.03.30
Background: As a negative regulator of P53, MDM2 plays an important role in carcinogenesis; a polymorphism in its promoter region. SNP309 T>G, is known to increase the expression of MDM2, thus being considered related to higher susceptibility to neoplasia. However, no agreement has been achieved regarding its effects on gastric cancer. Methods: The present systematic meta-analysis was performed based on comprehensive literature search from Pubmed, Web of science and CBM databases. Results: It was suggested from 6 independent studies that the GG genotype is associated with a significantly increased risk of gastric cancer (Recessive: OR = 1.43, 95% CI = 1.08-1.91, P = 0.013), and subgroup analysis also confirmed the relationship (English publications-recessive model: OR = 1.45, 95% CI = 1.10-1.91, P = 0.009; Studies in China-recessive model: OR = 1.58, 95% CI = 1.08-2.30, P = 0.017). No publication bias was detected. Conclusion: The meta-analysis indicated a significant inverse association between GG genotype carriage and elevated risk of gastric cancer. However, more studies and detailed information are needed to fully address the topic.
- Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602. https://doi.org/10.1016/j.cell.2004.11.022
- Bond GL, Hu W, Levine A (2005). A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res, 65, 5481-4. https://doi.org/10.1158/0008-5472.CAN-05-0825
- Cai X, Yang M (2012). The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol, 138, 555-61. https://doi.org/10.1007/s00432-011-1124-8
- Chen T, Yi SH, Liu XY, et al (2012). Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk. Asian Pac J Cancer Prev, 13, 4327-30. https://doi.org/10.7314/APJCP.2012.13.9.4327
- Cho YG, Choi BJ, Song JH, et al (2008). No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma, 55, 256-60.
- Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62.
- Eischen CM, Lozano G (2009). p53 and MDM2: antagonists or partners in crime? Cancer Cell, 15, 161-2. https://doi.org/10.1016/j.ccr.2009.02.004
- Er LM, Niu WW, Xu ZB, et al (2009). Relation of MDM2 gene polymorphism and Helicobacter pylori infection to gastric cardiac carcinoma. Clin Focus, 24, 1594-7.
- Er LM (2012). Relevance of MDM2 polymorphisms with esophageal squamous cell carcinoma, gastric adenocarcinoma and double primary cancers in esophagus and stomach. Modern Prev Med, 39, 3342-4.
- Gajjar M, Candeias MM, Malbert-Colas L, et al (2012). The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell, 21, 25-35. https://doi.org/10.1016/j.ccr.2011.11.016
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907. https://doi.org/10.1158/1055-9965.EPI-10-0437
- Knappskog S, Bjornslett M, Myklebust LM, et al (2011). The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell, 19, 273-82. https://doi.org/10.1016/j.ccr.2010.12.019
- Knappskog S, Lonning PE (2011). Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription, 2, 207-10. https://doi.org/10.4161/trns.2.5.16813
- Li YQ, et al (2010). Interaction of Helicobacter pylori with MDM2 SNP309 polymorphisms and susceptibility to gastric cancer studies. Nanjing Medical School.
- Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev, 12, 1899-903.
- Ma HB, Huang T, Han F, et al (2012). Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6. https://doi.org/10.7314/APJCP.2012.13.6.2841
- Ohmiya N, Taguchi A, Mabuchi N, et al (2006). MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 24, 4434-40. https://doi.org/10.1200/JCO.2005.04.1459
- Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
- Society AC (2013). Cancer Facts & Figures 2013. Atlanta: American Cancer Society.
- Stolte M, Meining A (1998) Helicobacter pylori and Gastric Cancer. Oncologist, 3, 124-8.
- Stommel JM, Wahl GM (2005). A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle, 4, 411-7. https://doi.org/10.4161/cc.4.3.1522
- Wang X, Yang J, et al (2009). Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 14, 114-9.
- Yang L (2006). Incidence and mortality of gastric cancer in China. World J Gastroenterol, 12, 17-20.
- Yang M, Guo Y, Zhang X, et al (2007). Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 28, 1996-2001. https://doi.org/10.1093/carcin/bgm168
- Zhang L, et al (2011). Association of gene polymorphisms with Helicobacter pylori related gastric cancer in a Chinese population. Chongqing Medical School.
- Zhao P, Dai M, Chen W, et al (2010). Cancer trends in China. Jpn J Clin Oncol, 40, 281-5. https://doi.org/10.1093/jjco/hyp187
- Lack of Association between Bax Promoter (-248G>A) Single Nucleotide Polymorphism and Susceptibility towards Cancer: Evidence from a Meta-Analysis vol.8, pp.10, 2013, https://doi.org/10.1371/journal.pone.0077534
- The MDM2 SNP309T>G Polymorphism Increases Bladder Cancer Risk among Caucasians: a Meta-analysis vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5277
- Effects of p53 Codon 72 and MDM2 SNP309 Polymorphisms on Gastric Cancer Risk among the Iranian Population vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7413
- Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and gastric cancer vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1219-8
- promoter polymorphisms and uterine leiomyoma in South-East Iran: A preliminary report vol.41, pp.5, 2014, https://doi.org/10.1111/jog.12625
- Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3759
- Role of E3 ubiquitin ligases in gastric cancer vol.21, pp.3, 2015, https://doi.org/10.3748/wjg.v21.i3.786
- Association of THBS1 rs1478605 T>C in 5′-untranslated regions with the development and progression of gastric cancer vol.3, pp.2, 2015, https://doi.org/10.3892/br.2015.414
- Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population vol.32, pp.1, 2015, https://doi.org/10.1007/s12032-014-0401-1
- Investigation of the association between the MDM2 T309G polymorphism and gastric cancer vol.7, pp.5, 2017, https://doi.org/10.3892/br.2017.978
Supported by : National Natural Science Foundation of China (nsfc)